Drug Profile
Research programme: gastro-oesophageal reflux therapy - Nycomed
Alternative Names: P-CABs - NycomedLatest Information Update: 11 Apr 2012
Price :
$50
*
At a glance
- Originator Nycomed
- Developer Takeda Pharmaceuticals International GmbH
- Class Imidazoles; Pyridines; Small molecules
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 01 Apr 2012 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (PO)
- 30 Sep 2011 Nycomed has been acquired by Takeda
- 02 Apr 2008 Preclinical development is ongoing